Axsome Therapeutics (AXSM) Interest Expenses (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Interest Expenses data on file, last reported at $6.4 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses changed 0.0% year-over-year to $6.4 million; the trailing twelve-month figure through Mar 2026 stood at $6.4 million (changed 0.0% YoY), and the FY2025 full-year result was $316.1 million, up 1564.76% from the prior year.
• Interest Expenses rose to $6.4 million in Q1 2026, from $3.0 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $117.1 million in Q3 2022 to a low of -$5.4 million in Q4 2024.
• A 5-year average of $19.4 million and a median of $6.4 million in 2023 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses jumped 467.17% in 2023 and slumped 211.54% in 2024, its largest moves.
• Tracing AXSM's Interest Expenses over 5 years: stood at $2.6 million in 2022, then surged by 89.49% to $4.9 million in 2023, then tumbled by 211.54% to -$5.4 million in 2024, then surged by 156.17% to $3.0 million in 2025, then jumped by 109.02% to $6.4 million in 2026.
• Business Quant data shows AXSM's Interest Expenses at $6.4 million in Q1 2026, $3.0 million in Q4 2025, and $29.9 million in Q3 2025.